VOYAGER THERAPEUTICS INC(NASDAQ:VYGR) stock News

VYGR Latest News, Press Relases and Analysis

All

Press Releases

12 days ago - By: Benzinga

Voyager Therapeutics Alzheimer's Portfolio And ALPL NeuroShuttle Underscore Platform Momentum: Analyst

a month ago - By: Voyager Therapeutics, Inc.

Voyager to Present at Upcoming Investor Conferences

2 months ago - By: Zacks Investment Research - Mentions: IMNM

Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates

2 months ago - By: Voyager Therapeutics, Inc.

Voyager Reports Second Quarter 2025 Financial and Operating Results

2 months ago - By: Voyager Therapeutics, Inc.

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

6 months ago - By: Benzinga

7 Analysts Assess Voyager Therapeutics: What You Need To Know

4 months ago - By: Voyager Therapeutics, Inc.

Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

4 months ago - By: Yahoo Finance - Mentions: AVGO VZ CRWD LULU ...

1 Stock to Buy, 1 Stock to Sell This Week: Broadcom, Lululemon

4 months ago - By: Yahoo Finance - Mentions: BRKA BRKB VRTX PLD ...

2 Top Stocks to Buy Right Now

4 months ago - By: Yahoo Finance - Mentions: TVRD BIDU AGYS LCID ...

Oppenheimer Predicts Up to ~550% Jump for These 2 ‘Strong Buy’ Stocks

5 months ago - By: Voyager Therapeutics, Inc.

Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication

5 months ago - By: Zacks Investment Research - Mentions: HOWL

Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates

5 months ago - By: Voyager Therapeutics, Inc.

Voyager Reports First Quarter 2025 Financial and Operating Results

5 months ago - By: Voyager Therapeutics, Inc.

Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting

6 months ago - By: Voyager Therapeutics, Inc.

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

6 months ago - By: Bragar Eagel & Squire - Mentions: DAVE RCAT PPTA

Bragar Eagel & Squire, P.C. Is Investigating Dave, Red Cat, Perpetua, and Voyager and Encourages Investors to Contact the Firm

6 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR

7 months ago - By: Voyager Therapeutics, Inc.

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

7 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR

7 months ago - By: Voyager Therapeutics, Inc.

Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast

7 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR

7 months ago - By: Voyager Therapeutics, Inc.

Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease

7 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR

7 months ago - By: Bragar Eagel & Squire

VOYAGER ALERT: Bragar Eagel & Squire, P.C. is Investigating Voyager Therapeutics, Inc. on Behalf of Voyager Stockholders and Encourages Investors to Contact the Firm

7 months ago - By: The Schall Law Firm

VYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

7 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR

11 months ago - By: Voyager Therapeutics, Inc.

Voyager Reports Third Quarter 2024 Financial and Operating Results

a year ago - By: Voyager Therapeutics, Inc.

VOYAGER THERAPEUTICS INC (VYGR) Stock News

VYGR Latest News, Press Relases and Analysis

Voyager Therapeutics Alzheimer's Portfolio And ALPL NeuroShuttle Underscore Platform Momentum: Analyst

Voyager to Present at Upcoming Investor Conferences

Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates

Voyager Reports Second Quarter 2025 Financial and Operating Results

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

7 Analysts Assess Voyager Therapeutics: What You Need To Know

Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

1 Stock to Buy, 1 Stock to Sell This Week: Broadcom, Lululemon

2 Top Stocks to Buy Right Now

Oppenheimer Predicts Up to ~550% Jump for These 2 ‘Strong Buy’ Stocks

Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication

Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates

Voyager Reports First Quarter 2025 Financial and Operating Results

Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

Bragar Eagel & Squire, P.C. Is Investigating Dave, Red Cat, Perpetua, and Voyager and Encourages Investors to Contact the Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR

Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR

Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR

VOYAGER ALERT: Bragar Eagel & Squire, P.C. is Investigating Voyager Therapeutics, Inc. on Behalf of Voyager Stockholders and Encourages Investors to Contact the Firm

VYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR

Voyager Reports Third Quarter 2024 Financial and Operating Results

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences